ESR1 and ductal breast carcinoma in situ: Metformin is also effective against HER2+ BC since it confers anti-proliferative effects in females with HER2+ BC co-expressed with ER+ with ductal carcinoma in situ (DCIS).131 Nonetheless, the molecular mechanisms behind these findings are inadequately explained.